Business in the Burbs

EpiCept pairs up with GNI to develop hepatitis drug

July

EpiCept Corp., a pharmaceutical company at The Landmark in Eastview, said it is partnering with GNI Ltd. to develop a new drug to treat late-stage viral infection-induced hepatitis.

GNI is a biopharmaceutical company with headquarters in Japan and major operations in China. The companies will develop the drug in Asia, Australia and New Zealand. Shanghai Genomics, a unit of GNI, will start to prepare for development in China.

EpiCept is earning an upfront license fee and will be eligible for milestone payments and royalties on commercial sales in return for granting GNI a license to develop the drug, known as EP1013. EP1013 was discovered by EpiCept scientists and is covered by patents in the United States, China and other markets.

More than 20 million people in China are affected by hepatitis B virus infection, EpiCept said.

This entry was posted on Friday, July 18th, 2008 at 5:25 am by Julie Moran Alterio. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Uncategorized

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.